| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC12020 | MK-8722 Featured | MK-8722 is a systemic, Direct Pan-Activator of AMP-Activated Protein Kinase. |
|
| DC10871 | MTX211 Featured | MTX-211 is a dual inhibitor of EGFR and PI3K, used for the treatment of cancer and other diseases. |
|
| DC7250 | NVP-BAG956(BAG 956) | NVP-BAG956(BAG 956) is a potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo,with IC50 values to be 56, 444, 34, 117 and 240 nM for PI3K p110 alpha, beta, delta and gamma and PDK1 kinases, respectively. |
|
| DC3133 | NVP-BGT226 (BGT226） Featured | NVP-BGT226 is a novel dual PI3K/mTOR inhibitor with IC50 of 1 nM. |
|
| DC10540 | NVP-BQR695 Featured | NVP-BQR695 is a novel PI3K inhibitor. |
|
| DC1006 | OSI-027 Featured | OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
|
| DC7220 | OSU-03012 Featured | OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067. |
|
| DC8732 | OTSSP167 Featured | OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like). |
|
| DC7475 | OTSSP167 HCl Featured | OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like). |
|
| DC9587 | PDK1 inhibitor | PDK1 inhibitor is a potent and selective inhibitor of PDK1 with potential as anticancer agent.. |
|
| DC2021 | Perifosine (KRX-0401) Featured | Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM. |
|
| DC8527 | PF-04979064 | PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor developed through structure-based drug design. It inhibited mTOR, PI3Kα, β, δ and γ isoforms and AKT phosphorylation with IC50 as 2.64 nM, 0.395 nM, 0.111 nM, 0.122 nM and 28. |
|
| DC11466 | PF-06409577 Featured | PF-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 isoform with an EC50 of 7 nM. |
|
| DC8395 | PF-4989216 Featured | PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively. |
|
| DC7481 | PHT427 Featured | PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively. |
|
| DC7232 | PI-103 Featured | PI103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (IC50= 2 nM), p110beta (IC50= 3 nM), p110delta (IC50= 3 nM), and p110gamma (IC50= 15 nM), less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. |
|
| DC7628 | PI-3065 Featured | PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR. |
|
| DC8335 | PQR-309(Bimiralisib) Featured | PI3K-IN-2 is a PI3K inhibitor, inhibits pPKB and pS6 with "++++/+++(+)" in A2058 melanoma cell. |
|
| DC9661 | PIK-293 Featured | PIK-293 is a PI3K inhibitor, mostly for PI3Kδ with IC50 of 0.24 μM, 500-, 100- and 50-fold less potent to PI3Kα/β/γ, respectively. |
|
| DC7234 | PIK-294 Featured | PIK-294 is a highly selective p110δ inhibitor with IC50 of 10 nM, 1000-, 49- and 16-fold less potent to PI3Kα/β/γ, respectively. |
|
| DC1096 | PIK90 Featured | PIK-90 is a potent and cell permeable inhibitor of p110α, p110β, p110γ and p110δ with IC50 of 11 nM, 350 nM, 18 nM and 58 nM, respectively. |
|
| DC8254 | PIK-93 Featured | PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM. |
|
| DC9747 | PIK-III Featured | PIK-III, which is a selective inhibitor of VPS34 enzymatic activity, inhibits autophagy and de novo lipidation of LC3 and leads to the stabilization of autophagy substrates. |
|
| DC7123 | PKI402 | PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R. |
|
| DC7238 | Gedatolisib(PKI-587) Featured | PKI-587 is a highly potent dual PI3K/mTOR kinase inhibitor with IC50 of 0.4 nM and <0.1 μM for PI3K-α and mTOR, respectively. |
|
| DC8742 | PP121 | PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM. |
|
| DC7482 | Torkinib (PP242) Featured | PP242 is a selective mTOR inhibitor with IC50 of 8 nM; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively; also showed slightly weaker activity against BRD4 (Kd= 1.7 uM). |
|
| DC10767 | PQR530 Featured | PQR530 is a selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor. |
|
| DC11816 | RapaLink-1 Featured | RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin. |
|
| DC1048 | Rapamycin (Sirolimus) Featured | Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor with IC50 of ~0.1 nM. - |
|
